Genome Editing of HBG1/2 Promoter Leads to Robust Hbf Induction in Vivo While Editing of BCL11A Erythroid Enhancer Shows Erythroid Defect

Total Page:16

File Type:pdf, Size:1020Kb

Genome Editing of HBG1/2 Promoter Leads to Robust Hbf Induction in Vivo While Editing of BCL11A Erythroid Enhancer Shows Erythroid Defect Genome Editing of HBG1/2 Promoter Leads to Robust HbF Induction In Vivo While Editing of BCL11A Erythroid Enhancer Shows Erythroid Defect Kai-Hsin Chang, Minerva Sanchez, Jack Heath, Edouard de Dreuzy, Scott Haskett, Abigail Vogelaar, Kiran Gogi, Jen DaSilva, Tongyao Wang, Andrew Sadowski, Gregory Gotta, Jamaica Siwak, Ramya Viswanathan, Katherine Loveluck, Hoson Chao, Eric Tillotson, Aditi Chalishazar, Abhishek Dass, Frederick Ta, Emily Brennan, Diana Tabbaa, Eugenio Marco, John Zuris, Deepak Reyon, Meltem Isik, Ari Friedland, Terence Ta, Fred Harbinski, Georgia Giannoukos, Sandra Teixeira, Christopher Wilson, Charlie Albright, Haiyan Jiang Editas Medicine, Inc., Cambridge, MA 60th Annual Meeting and Exposition of American Society of Hematology December 2, 2018, San Diego, CA © 2018 Editas Medicine Overview Etiology of Sickle Cell Disease In Vivo Study Design to Evaluate Two Approaches to Increase Fetal Hemoglobin (HbF) Expression Effect of Downregulating BCL11A Expression by Targeting its Erythroid Enhancer Editing Cis-regulatory Elements in b-Globin Locus Conclusion © 2018 Editas Medicine Etiology of Sickle Cell Disease Amino Hemoglobin Low DNA Acid Tetramer O2 a a a a b-globin GLU G A G b b b b HbA a a a a a a a a s s s VAL b b b -globin G T G bs bs bs bs bs bs HbS HbS Fiber • Sickle cell disease (SCD) is caused by a single mutation E6V of the b-globin chain, leading to polymerization of hemoglobin (Hb) and formation of sickle hemoglobin (HbS) fibers when deoxygenated. • Symptoms include anemia, acute chest syndrome, pain crises, and an array of other complications. • Patients suffer significant morbidity and early mortality. Bender MA. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. Gene Reviews® [Internet]. © 2018 Editas Medicine Seattle (WA): University of Washington, Seattle; 1993-2018. Harnessing Natural Anti-sickling Hemoglobin to Treat Sickle Cell Disease Embryo Fetus Adult b-globin locus HBE HBG2 HBG1 HBD HBB Insulator Enhancer Insulator (5’HS) (HS1-4) (3’HS1) LCR a a a a g g HbS b b HbF HbA 100 a g 75 b a a a a g g b b Onset of Globin switch 50 e SCD 25 Symptoms % Globin % Synthesis Globin d 0 0 3 6 9 12 15 18 Months Post-conception Adapted from Canver and Orkin, Blood, 2016 © 2018 Editas Medicine Genome Editing to Reverse Hemoglobin Switching for Treating Sickle Cell Disease CRISPR-based disruption of HbF-repressing machinery Engineered patient Patient CD34+ cells* CD34+ cells* with switching reversed a a a a a a bs bs g g bs bs HbS HbF HbS *CD34+ hematopoietic stem and progenitor cells (HSPCs) © 2018 Editas Medicine Preclinical Target Criteria Successful Maintenance Robust editing of of normal long-term long-term HSPC induction of HSCs functions HbF © 2018 Editas Medicine Study Design for Assessment of Multilineage Engraftment Potential of Edited HSPCs Intravenous (IV) Bone marrow infusion (BM) collection Edited of mock 8-16 weeks transfected CD34+ cells NBSGW Mice 1 Lineage reconstitution by flow cytometry Human Chimerism Erythroid B Cell Monocyte Neutrophils HSPCs hCD45/WBC CD235a/total hCD19/hCD45 hCD14/hCD45 hCD15/hCD45 hCD34/hCD45 2 Editing analysis by Next-Gen Sequencing (NGS) • Unfractionated BM • Flow sorted erythroids, B cells, neutrophils, and Lin-HSPCs 3 Analysis of HbF (γ/β-like) expression by reverse phase UPLC • Flow sorted CD235a+ erythroid cells • Ex vivo cultured erythroid cells froM chiMeric BM 4 Apoptosis assessment of cultured erythroid cells by flow cytometry © 2018 Editas Medicine Approach 1: Downregulation of BCL11A Expression by Targeting Its Erythroid Enhancer Intron2 GATAA chr2 BCL11A Erythroid-specific enhancer BCL11A chr11 HBE HBG2 HBG1 HBD HBB b-globin locus Insulator Enhancer Insulator (5’HS) (HS1-4) a a (3’HS1) LCR a a g g bs bs HbF HbS © 2018 Editas Medicine BCL11A Erythroid Enhancer-editing Displayed Reduced Erythroid Output in BM of NBSGW Mice 90 85 80 Control 75 BCL11A 70 p<0.001 15 *** 10 Population (%) Population 5 *** 0 hCD45 CD235a CD14 CD15 CD19 CD34 Leukocyte Erythroid Monocyte Neutrophil B-cell HSPC © 2018 Editas Medicine Reduced BCL11A Erythroid Output Coincided with Increased Non-productive Indels and Increased Apoptosis BM Sorted erythroid cells Cultured erythroids Reduced Increased Less editing Enrichment Of erythroid output non-productive edits apoptosis 120 *** 120 *** 300 *** 6 *** 100 100 productive 80 80 - 200 4 60 60 Indels (%) Indels 40 40 100 2 20 20 Cells % Caspase+ % Control (Erythroid) % Control Normalized Indels (%) Normalized non 0 0 0 0 BM BM Control Control BCL11A BCL11A Erythroid Erythroid p<0.001 © 2018 Editas Medicine BCL11A Erythroid Enhancer-editing Failed to Meet Preclinical Target Criteria Successful Maintenance Robust editing of of normal long-term long-term HSPC induction of HSCs functions HbF © 2018 Editas Medicine Approach 2: Editing Cis-regulatory Elements in b-Globin Locus Adult Fetus Embryo HBB HBD HBG1 HBG2 HBE b-globin locus Insulator Enhancer Insulator (3’HS1) (HS1-4) (5’HS) LCR HBB HBG1-2 (2) 2 t n e 2 m h c i r n 1 e g v 1 a . g v A 0 HBE LCR 0 HBB-HBG Log2 Enrichment Log2 -1 5120K 5140K 5160K 5180K 5200K 5220K 5240K 5260K 5280K 5300K 5320K 5340K 5360K 5380K 5400K 5420K 5440K coordinates • ~26,000 gRNAs were testeD covering 320kb genomic region • ~300 HbF-inDucing gRNA were iDentifieD • Most were mappeD to b-globin locus incluDing HBG, HBD, and HBB genes © 2018 Editas MeDicine Robust HbF Induction Achieved with Editing of HBG1/2 Promoters Ex Vivo 50 40 30 like) (%) - b / g 20 ( HbF 10 0 Control HBG1/2 Multiple enzymes including SpCas9, SaCas9, Cpf1 (Cas12a) and gRNA combinations were tested © 2018 Editas Medicine HBG1/2 Promoter-editing Displayed Normal Erythroid Output in BM of NBSGW Mice 90 85 80 Control 75 HBG1/2 70 15 10 Population (%) Population 5 0 hCD45 CD235a CD14 CD15 CD19 CD34 Leukocyte Erythroid Monocyte Neutrophil B-cell HSPC © 2018 Editas Medicine HBG1/2 Promoter Editing Demonstrated No Erythroid Defect BM Sorted erythroid cells Cultured erythroids Similar levels of Similar levels of indels in Similar levels erythroid output erythroid compared to BM of apoptosis 120 120 300 6 100 100 80 80 productive 200 4 - 60 60 40 40 (%) Indels 100 2 20 20 Cells % Caspase+ % Control (Erythroid) % Control Normalized Indels (%) 0 0 Normalized non 0 0 BM BM Control Control HBG1/2 HBG1/2 Erythroid Erythroid © 2018 Editas Medicine HBG1/2 Promoter Editing Demonstrated Long-term HbF Induction *** *** 30 20 like) (%) - b / g ( 10 HbF 0 Control HBG1/2 Control HBG1/2 CD235a Cultured erythroid Erythroid from BM p<0.001 © 2018 Editas Medicine Editing HBG1/2 Promoters Met Critical Preclinical Target Criteria Successful Maintenance Robust editing of of normal long-term long-term HSPC induction of HSCs functions HbF © 2018 Editas Medicine Conclusions Long-term engraftment observed in immunocompromised NBSGW mice with both BCL11A erythroid enhancer-edited and HBG1/2 promoter-edited CD34+ HSPCs In this study, BCL11A-edited CD34+ HSPCs had an erythroid differentiation defect in the NBSGW mouse model that was not observed in HBG1/2-edited CD34+ HSPCs Robust induction of HbF in HBG1/2 promoter-edited erythroid cells from long-term in vivo study © 2018 Editas Medicine Acknowledgements Pipeline Platform Program Management CMC Clinical Lab Operations © 2018 Editas Medicine.
Recommended publications
  • Identifying and Mapping Cell-Type-Specific Chromatin PNAS PLUS Programming of Gene Expression
    Identifying and mapping cell-type-specific chromatin PNAS PLUS programming of gene expression Troels T. Marstranda and John D. Storeya,b,1 aLewis-Sigler Institute for Integrative Genomics, and bDepartment of Molecular Biology, Princeton University, Princeton, NJ 08544 Edited by Wing Hung Wong, Stanford University, Stanford, CA, and approved January 2, 2014 (received for review July 2, 2013) A problem of substantial interest is to systematically map variation Relating DHS to gene-expression levels across multiple cell in chromatin structure to gene-expression regulation across con- types is challenging because the DHS represents a continuous ditions, environments, or differentiated cell types. We developed variable along the genome not bound to any specific region, and and applied a quantitative framework for determining the exis- the relationship between DHS and gene expression is largely tence, strength, and type of relationship between high-resolution uncharacterized. To exploit variation across cell types and test chromatin structure in terms of DNaseI hypersensitivity and genome- for cell-type-specific relationships between DHS and gene expres- wide gene-expression levels in 20 diverse human cell types. We sion, the measurement units must be placed on a common scale, show that ∼25% of genes show cell-type-specific expression ex- the continuous DHS measure associated to each gene in a well- plained by alterations in chromatin structure. We find that distal defined manner, and all measurements considered simultaneously. regions of chromatin structure (e.g., ±200 kb) capture more genes Moreover, the chromatin and gene-expression relationship may with this relationship than local regions (e.g., ±2.5 kb), yet the local only manifest in a single cell type, making standard measures of regions show a more pronounced effect.
    [Show full text]
  • Hypoxia-Induced Alpha-Globin Expression in Syncytiotrophoblasts Mimics the Pattern Observed in Preeclamptic Placentas
    International Journal of Molecular Sciences Article Hypoxia-Induced Alpha-Globin Expression in Syncytiotrophoblasts Mimics the Pattern Observed in Preeclamptic Placentas Zahra Masoumi 1,* , Lena Erlandsson 1, Eva Hansson 1, Mattias Magnusson 2, Eva Mezey 3 and Stefan R. Hansson 1,4 1 Department of Clinical Sciences Lund, Division of Obstetrics and Gynecology, Lund University, SE-22184 Lund, Sweden; [email protected] (L.E.); [email protected] (E.H.); [email protected] (S.R.H.) 2 Department of Molecular Medicine and Gene Therapy, Lund University, SE-22184 Lund, Sweden; [email protected] 3 Adult Stem Cell Section, National Institute of Dental and Craniofacial Research, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, USA; [email protected] 4 Skåne University Hospital, SE-22184 Lund, Sweden * Correspondence: [email protected] Abstract: Preeclampsia (PE) is a pregnancy disorder associated with placental dysfunction and elevated fetal hemoglobin (HbF). Early in pregnancy the placenta harbors hematopoietic stem and progenitor cells (HSPCs) and is an extramedullary source of erythropoiesis. However, globin ex- pression is not unique to erythroid cells and can be triggered by hypoxia. To investigate the role of the placenta in increasing globin levels previously reported in PE, flow cytometry, histological and Citation: Masoumi, Z.; Erlandsson, immunostaining and in situ analyses were used on placenta samples and ex vivo explant cultures. L.; Hansson, E.; Magnusson, M.; Our results indicated that in PE pregnancies, placental HSPC homing and erythropoiesis were not Mezey, E.; Hansson, S.R. affected. Non-erythroid alpha-globin mRNA and protein, but not gamma-globin, were detected in Hypoxia-Induced Alpha-Globin Expression in Syncytiotrophoblasts syncytiotrophoblasts and stroma of PE placenta samples.
    [Show full text]
  • Serum Albumin OS=Homo Sapiens
    Protein Name Cluster of Glial fibrillary acidic protein OS=Homo sapiens GN=GFAP PE=1 SV=1 (P14136) Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=2 Cluster of Isoform 3 of Plectin OS=Homo sapiens GN=PLEC (Q15149-3) Cluster of Hemoglobin subunit beta OS=Homo sapiens GN=HBB PE=1 SV=2 (P68871) Vimentin OS=Homo sapiens GN=VIM PE=1 SV=4 Cluster of Tubulin beta-3 chain OS=Homo sapiens GN=TUBB3 PE=1 SV=2 (Q13509) Cluster of Actin, cytoplasmic 1 OS=Homo sapiens GN=ACTB PE=1 SV=1 (P60709) Cluster of Tubulin alpha-1B chain OS=Homo sapiens GN=TUBA1B PE=1 SV=1 (P68363) Cluster of Isoform 2 of Spectrin alpha chain, non-erythrocytic 1 OS=Homo sapiens GN=SPTAN1 (Q13813-2) Hemoglobin subunit alpha OS=Homo sapiens GN=HBA1 PE=1 SV=2 Cluster of Spectrin beta chain, non-erythrocytic 1 OS=Homo sapiens GN=SPTBN1 PE=1 SV=2 (Q01082) Cluster of Pyruvate kinase isozymes M1/M2 OS=Homo sapiens GN=PKM PE=1 SV=4 (P14618) Glyceraldehyde-3-phosphate dehydrogenase OS=Homo sapiens GN=GAPDH PE=1 SV=3 Clathrin heavy chain 1 OS=Homo sapiens GN=CLTC PE=1 SV=5 Filamin-A OS=Homo sapiens GN=FLNA PE=1 SV=4 Cytoplasmic dynein 1 heavy chain 1 OS=Homo sapiens GN=DYNC1H1 PE=1 SV=5 Cluster of ATPase, Na+/K+ transporting, alpha 2 (+) polypeptide OS=Homo sapiens GN=ATP1A2 PE=3 SV=1 (B1AKY9) Fibrinogen beta chain OS=Homo sapiens GN=FGB PE=1 SV=2 Fibrinogen alpha chain OS=Homo sapiens GN=FGA PE=1 SV=2 Dihydropyrimidinase-related protein 2 OS=Homo sapiens GN=DPYSL2 PE=1 SV=1 Cluster of Alpha-actinin-1 OS=Homo sapiens GN=ACTN1 PE=1 SV=2 (P12814) 60 kDa heat shock protein, mitochondrial OS=Homo
    [Show full text]
  • Adult, Embryonic and Fetal Hemoglobin Are Expressed in Human Glioblastoma Cells
    514 INTERNATIONAL JOURNAL OF ONCOLOGY 44: 514-520, 2014 Adult, embryonic and fetal hemoglobin are expressed in human glioblastoma cells MARWAN EMARA1,2, A. ROBERT TURNER1 and JOAN ALLALUNIS-TURNER1 1Department of Oncology, University of Alberta and Alberta Health Services, Cross Cancer Institute, Edmonton, AB T6G 1Z2, Canada; 2Center for Aging and Associated Diseases, Zewail City of Science and Technology, Cairo, Egypt Received September 7, 2013; Accepted October 7, 2013 DOI: 10.3892/ijo.2013.2186 Abstract. Hemoglobin is a hemoprotein, produced mainly in Introduction erythrocytes circulating in the blood. However, non-erythroid hemoglobins have been previously reported in other cell Globins are hemo-containing proteins, have the ability to types including human and rodent neurons of embryonic bind gaseous ligands [oxygen (O2), nitric oxide (NO) and and adult brain, but not astrocytes and oligodendrocytes. carbon monoxide (CO)] reversibly. They have been described Human glioblastoma multiforme (GBM) is the most aggres- in prokaryotes, fungi, plants and animals with an enormous sive tumor among gliomas. However, despite extensive basic diversity of structure and function (1). To date, hemoglobin, and clinical research studies on GBM cells, little is known myoglobin, neuroglobin (Ngb) and cytoglobin (Cygb) repre- about glial defence mechanisms that allow these cells to sent the vertebrate globin family with distinct function and survive and resist various types of treatment. We have tissue distributions (2). During ontogeny, developing erythro- shown previously that the newest members of vertebrate blasts sequentially express embryonic {[Gower 1 (ζ2ε2), globin family, neuroglobin (Ngb) and cytoglobin (Cygb), are Gower 2 (α2ε2), and Portland 1 (ζ2γ2)] to fetal [Hb F(α2γ2)] expressed in human GBM cells.
    [Show full text]
  • Technical Note, Appendix: an Analysis of Blood Processing Methods to Prepare Samples for Genechip® Expression Profiling (Pdf, 1
    Appendix 1: Signature genes for different blood cell types. Blood Cell Type Source Probe Set Description Symbol Blood Cell Type Source Probe Set Description Symbol Fraction ID Fraction ID Mono- Lympho- GSK 203547_at CD4 antigen (p55) CD4 Whitney et al. 209813_x_at T cell receptor TRG nuclear cytes gamma locus cells Whitney et al. 209995_s_at T-cell leukemia/ TCL1A Whitney et al. 203104_at colony stimulating CSF1R lymphoma 1A factor 1 receptor, Whitney et al. 210164_at granzyme B GZMB formerly McDonough (granzyme 2, feline sarcoma viral cytotoxic T-lymphocyte- (v-fms) oncogene associated serine homolog esterase 1) Whitney et al. 203290_at major histocompatibility HLA-DQA1 Whitney et al. 210321_at similar to granzyme B CTLA1 complex, class II, (granzyme 2, cytotoxic DQ alpha 1 T-lymphocyte-associated Whitney et al. 203413_at NEL-like 2 (chicken) NELL2 serine esterase 1) Whitney et al. 203828_s_at natural killer cell NK4 (H. sapiens) transcript 4 Whitney et al. 212827_at immunoglobulin heavy IGHM Whitney et al. 203932_at major histocompatibility HLA-DMB constant mu complex, class II, Whitney et al. 212998_x_at major histocompatibility HLA-DQB1 DM beta complex, class II, Whitney et al. 204655_at chemokine (C-C motif) CCL5 DQ beta 1 ligand 5 Whitney et al. 212999_x_at major histocompatibility HLA-DQB Whitney et al. 204661_at CDW52 antigen CDW52 complex, class II, (CAMPATH-1 antigen) DQ beta 1 Whitney et al. 205049_s_at CD79A antigen CD79A Whitney et al. 213193_x_at T cell receptor beta locus TRB (immunoglobulin- Whitney et al. 213425_at Homo sapiens cDNA associated alpha) FLJ11441 fis, clone Whitney et al. 205291_at interleukin 2 receptor, IL2RB HEMBA1001323, beta mRNA sequence Whitney et al.
    [Show full text]
  • Molecular Epidemiology and Hematologic Characterization of Δβ
    Jiang et al. BMC Medical Genetics (2020) 21:43 https://doi.org/10.1186/s12881-020-0981-x RESEARCH ARTICLE Open Access Molecular epidemiology and hematologic characterization of δβ-thalassemia and hereditary persistence of fetal hemoglobin in 125,661 families of greater Guangzhou area, the metropolis of southern China Fan Jiang1,2, Liandong Zuo2, Dongzhi Li2, Jian Li2, Xuewei Tang2, Guilan Chen2, Jianying Zhou2, Hang Lu2 and Can Liao1,2* Abstract Background: Individuals with δβ-thalassemia/HPFH and β-thalassemia usually present with intermedia or thalassemia major. No large-scale survey on HPFH/δβ-thalassemia in southern China has been reported to date. The purpose of this study was to examine the molecular epidemiology and hematologic characteristics of these disorders in Guangzhou, the largest city in Southern China, to offer advice for thalassemia screening programs and genetic counseling. Methods: A total of 125,661 couples participated in pregestational thalassemia screening. 654 subjects with fetal hemoglobin (HbF) level ≥ 5% were selected for further investigation. Gap-PCR combined with Multiplex ligation dependent probe amplification (MLPA) was used to screen for β-globin gene cluster deletions. Gene sequencing for the promoter region of HBG1 /HBG2 gene was performed for all those subjects. Results: A total of 654 individuals had hemoglobin (HbF) levels≥5, and 0.12% of the couples were found to be heterozygous for HPFH/δβ-thalassemia, including Chinese Gγ (Aγδβ)0-thal, Southeast Asia HPFH (SEA-HPFH), Taiwanese deletion and Hb Lepore–Boston–Washington. The highest prevalence was observed in the Huadu district and the lowest in the Nansha district. Three cases were identified as carrying β-globin gene cluster deletions, which had not been previously reported.
    [Show full text]
  • Identification of Novel HPFH-Like Mutations by CRISPR Base Editing That Elevates the Expression of Fetal Hemoglobin
    bioRxiv preprint doi: https://doi.org/10.1101/2020.06.30.178715; this version posted July 1, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Identification of novel HPFH-like mutations by CRISPR base editing that elevates the expression of fetal hemoglobin Nithin Sam Ravi1,3, Beeke Wienert4,8,9, Stacia K. Wyman4, Jonathan Vu4, Aswin Anand Pai2, Poonkuzhali Balasubramanian2, Yukio Nakamura7, Ryo Kurita10, Srujan Marepally1, Saravanabhavan Thangavel1, Shaji R. Velayudhan1,2, Alok Srivastava1,2, Mark A. DeWitt 4,5, Jacob E. Corn4,6, Kumarasamypet M. Mohankumar1* 1. Centre for Stem Cell Research (a unit of inStem, Bengaluru), Christian Medical College Campus, Bagayam, Vellore-632002, Tamil Nadu, India. 2. Department of Haematology, Christian Medical College Hospital, IDA Scudder Rd, Vellore-632002, Tamil Nadu, India. 3. Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram - 695 011, Kerala, India. 4. Innovative Genomics Institute, University of California Berkeley, Berkeley, California- 94704, USA. 5. Department of Microbiology, Immunology, and Molecular Genetics, University of California - Los Angeles, Los Angeles, California - 90095, USA. 6. Institute of Molecular Health Sciences, Department of Biology, ETH Zurich, Otto-Stern- Weg, Zurich - 8092, Switzerland. 7. Cell Engineering Division, RIKEN BioResource Center, Tsukuba, Ibaraki 305-0074, Japan. 8. Institute of Data Science and Biotechnology, Gladstone Institutes, San Francisco, California -94158, USA 9. School of Biotechnology and Biomolecular Sciences, University of New South Wales - 2052, Sydney, Australia. 10. Research and Development Department Central Blood Institute Blood Service Headquarters Japanese Red Cross Society, 2-1-67 Tatsumi, Tokyo, 135-8521, Japan *Corresponding Author: Dr.
    [Show full text]
  • Hemoglobin Sickle D Punjab—A Case Report
    154 Case Report Hemoglobin sickle D Punjab—a case report M. B. Mukherjee, R. R. Surve, R. R. Gangakhedkar, D. Mohanty, R. B. Colah Institute of Immunohaematology, Parel, Mumbai, India. Case History Compound heterozygosity for βS/βD results in a severe hemolytic anemia and a clinical syndrome similar to that of sickle cell disease. Here, we report a case of HbSD Punjab disease. A 10 year old female child residing at Nagpur, A 10 year old female child from Nagpur was referred Maharashtra presented with severe hemolytic anemia, to us with severe hemolytic anemia, occasional episodes hepatosplenomegaly and occasional pains in bones and of pains (predominantly bones and abdomen) associ- abdomen. Initially, she was thought to be a case of sickle cell anemia, however, with the help of HPLC and molecu- ated with fever. She had also received three units of lar analysis it was confirmed as HbSD Punjab disease. blood. Physical examination revealed short stature Key words: HbSD Punjab, Sickle cell disease, Haplotype, (weight 12.5 kg and height 105 cm), pallor, hepatome- α-geonotype galy (2 cm) and splenomegaly (3 cm) below the right and left costal margins respectively. Cardiovascular, res- piratory and nervous systems were normal. HbD Punjab also known as HbD Los Angeles is a β- chain variant and is characterized by a Glu→Gln sub- Investigations stitution at codon 121 with a GAA→CAA change at the DNA level and the electrophotetic mobility at alkaline Her Hb was 5.9 g/dl and the reticulocyte count was pH is similar to HbS (β6, Glu→Val).[1] HbD has been 3.3%.
    [Show full text]
  • Normal, C=Critical
    Patient Report |FINAL Client: Example Client ABC123 Patient: Patient, Example 123 Test Drive Salt Lake City, UT 84108 DOB 7/22/1970 UNITED STATES Gender: Female Patient Identifiers: 01234567890ABCD, 012345 Physician: Doctor, Example Visit Number (FIN): 01234567890ABCD Collection Date: 00/00/0000 00:00 Hemoglobin Evaluation Reflexive Cascade ARUP test code 2005792 Hemoglobin A 97.1 % (Ref Interval: 95.0-97.9) Hemoglobin A2 2.6 % (Ref Interval: 2.0-3.5) Hemoglobin F 0.3 % (Ref Interval: 0.0-2.1) REFERENCE INTERVAL: Hemoglobin F Access complete set of age- and/or gender-specific reference intervals for this test in the ARUP Laboratory Test Directory (aruplab.com). Hemoglobin S 0.0 % (Ref Interval: 0.0-0.0) Hemoglobin C 0.0 % (Ref Interval: 0.0-0.0) Hemoglobin E 0.0 % (Ref Interval: 0.0-0.0) Hemoglobin - Other 0.0 % (Ref Interval: 0.0-0.0) Sickle Cell Solubility Not Performed Hemoglobin, Capillary Electrophoresis Performed Hemoglobin Evaluation See Note Beta Globin Full Gene Sequencing Not Applicable H=High, L=Low, *=Abnormal, C=Critical Patient: Patient, Example ARUP Accession: 21-048-400496 Patient Identifiers: 01234567890ABCD, 012345 Visit Number (FIN): 01234567890ABCD Page 1 of 4 | Printed: 3/11/2021 11:41:09 AM 4848 Patient Report |FINAL Beta Globin (HBB) Del/Dup Result Not Applicable Alpha Thalassemia HBA1 and HBA2 Seq Not Applicable Gamma Globin (HBG1 and HBG2) Sequencing Not Applicable Hemoglobin Cascade Interpretation See Note H=High, L=Low, *=Abnormal, C=Critical Patient: Patient, Example ARUP Accession: 21-048-400496 Patient Identifiers: 01234567890ABCD, 012345 Visit Number (FIN): 01234567890ABCD Page 2 of 4 | Printed: 3/11/2021 11:41:09 AM 4848 Patient Report |FINAL RESULT Normal hemoglobin evaluation.
    [Show full text]
  • Apoptotic Cells Inflammasome Activity During the Uptake of Macrophage
    Downloaded from http://www.jimmunol.org/ by guest on September 29, 2021 is online at: average * The Journal of Immunology , 26 of which you can access for free at: 2012; 188:5682-5693; Prepublished online 20 from submission to initial decision 4 weeks from acceptance to publication April 2012; doi: 10.4049/jimmunol.1103760 http://www.jimmunol.org/content/188/11/5682 Complement Protein C1q Directs Macrophage Polarization and Limits Inflammasome Activity during the Uptake of Apoptotic Cells Marie E. Benoit, Elizabeth V. Clarke, Pedro Morgado, Deborah A. Fraser and Andrea J. Tenner J Immunol cites 56 articles Submit online. Every submission reviewed by practicing scientists ? is published twice each month by Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://jimmunol.org/subscription http://www.jimmunol.org/content/suppl/2012/04/20/jimmunol.110376 0.DC1 This article http://www.jimmunol.org/content/188/11/5682.full#ref-list-1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material References Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2012 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of September 29, 2021. The Journal of Immunology Complement Protein C1q Directs Macrophage Polarization and Limits Inflammasome Activity during the Uptake of Apoptotic Cells Marie E.
    [Show full text]
  • Molecular Profiling of Innate Immune Response Mechanisms in Ventilator-Associated 2 Pneumonia
    bioRxiv preprint doi: https://doi.org/10.1101/2020.01.08.899294; this version posted January 9, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 Title: Molecular profiling of innate immune response mechanisms in ventilator-associated 2 pneumonia 3 Authors: Khyatiben V. Pathak1*, Marissa I. McGilvrey1*, Charles K. Hu3, Krystine Garcia- 4 Mansfield1, Karen Lewandoski2, Zahra Eftekhari4, Yate-Ching Yuan5, Frederic Zenhausern2,3,6, 5 Emmanuel Menashi3, Patrick Pirrotte1 6 *These authors contributed equally to this work 7 Affiliations: 8 1. Collaborative Center for Translational Mass Spectrometry, Translational Genomics Research 9 Institute, Phoenix, Arizona 85004 10 2. Translational Genomics Research Institute, Phoenix, Arizona 85004 11 3. HonorHealth Clinical Research Institute, Scottsdale, Arizona 85258 12 4. Applied AI and Data Science, City of Hope Medical Center, Duarte, California 91010 13 5. Center for Informatics, City of Hope Medical Center, Duarte, California 91010 14 6. Center for Applied NanoBioscience and Medicine, University of Arizona, Phoenix, Arizona 15 85004 16 Corresponding author: 17 Dr. Patrick Pirrotte 18 Collaborative Center for Translational Mass Spectrometry 19 Translational Genomics Research Institute 20 445 North 5th Street, Phoenix, AZ, 85004 21 Tel: 602-343-8454; 22 [[email protected]] 23 Running Title: Innate immune response in ventilator-associated pneumonia 24 Key words: ventilator-associated pneumonia; endotracheal aspirate; proteome, metabolome; 25 neutrophil degranulation 26 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.01.08.899294; this version posted January 9, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder.
    [Show full text]
  • Identifying Genetic Variants and Pathways Associated with Extreme Levels of Fetal Hemoglobin in Sickle Cell Disease in Tanzania
    Nkya et al. BMC Medical Genetics (2020) 21:125 https://doi.org/10.1186/s12881-020-01059-1 RESEARCH ARTICLE Open Access Identifying genetic variants and pathways associated with extreme levels of fetal hemoglobin in sickle cell disease in Tanzania Siana Nkya1,2*, Liberata Mwita2, Josephine Mgaya2, Happiness Kumburu3, Marco van Zwetselaar3, Stephan Menzel4, Gaston Kuzamunu Mazandu5,6,7* , Raphael Sangeda2,8, Emile Chimusa5 and Julie Makani2 Abstract Background: Sickle cell disease (SCD) is a blood disorder caused by a point mutation on the beta globin gene resulting in the synthesis of abnormal hemoglobin. Fetal hemoglobin (HbF) reduces disease severity, but the levels vary from one individual to another. Most research has focused on common genetic variants which differ across populations and hence do not fully account for HbF variation. Methods: We investigated rare and common genetic variants that influence HbF levels in 14 SCD patients to elucidate variants and pathways in SCD patients with extreme HbF levels (≥7.7% for high HbF) and (≤2.5% for low HbF) in Tanzania. We performed targeted next generation sequencing (Illumina_Miseq) covering exonic and other significant fetal hemoglobin-associated loci, including BCL11A, MYB, HOXA9, HBB, HBG1, HBG2, CHD4, KLF1, MBD3, ZBTB7A and PGLYRP1. Results: Results revealed a range of genetic variants, including bi-allelic and multi-allelic SNPs, frameshift insertions and deletions, some of which have functional importance. Notably, there were significantly more deletions in individuals with high HbF levels (11% vs 0.9%). We identified frameshift deletions in individuals with high HbF levels and frameshift insertions in individuals with low HbF. CHD4 and MBD3 genes, interacting in the same sub-network, were identified to have a significant number of pathogenic or non-synonymous mutations in individuals with low HbF levels, suggesting an important role of epigenetic pathways in the regulation of HbF synthesis.
    [Show full text]